Back to Results
First PageMeta Content
Anatomy / Biology / Diabetes / Anorectics / Eli Lilly and Company / Exenatide / Monoclonal antibodies / Monoclonal antibody therapy / Glucagon-like peptide-1 / Anti-diabetic drugs / Immunology / Medicine


FOR IMMEDIATE RELEASE INTARCIA AND NUMAB SIGN MULTI-ASSET COLLABORATION TO DEVELOP ONCEYEARLY THERAPIES IN DIABETES, OBESITY, AND AUTOIMMUNE INDICATIONS  Collaboration combines Intarcia’s proprietary delivery tech
Add to Reading List

Document Date: 2015-03-19 15:54:18


Open Document

File Size: 256,89 KB

Share Result on Facebook
UPDATE